Abstract
ObjectivesTo evaluate the efficacy and safety of avacopan in the subgroup of patients with antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis receiving background induction therapy with rituximab in the phase 3 ADVOCATE...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have